9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis
SAR444200 is a novel NANOBODY® T cell engager that simultaneously binds TCRαβ and glypican-3 (GPC3) to co-engage T cells with GPC3+ tumor cells, resulting in T cell-dependent cellular cytotoxicity. Here, we present updated safety and pharmacokinetic (PK) data from the dose escalation cohort (Part 1A) of the multicenter, first in human phase 1/2 trial (NCT05450562).
Authors
- Ran Meng (ORCID: https://orcid.org/0000-0001-8452-8758)
- Hélène Guillemin‐Paveau
- Serena Masciari
- Jung Yong Hong (ORCID: https://orcid.org/0000-0003-1363-9332)
- K. Almhanna
- B-C. Goh
- Wan‐Teck Lim (ORCID: https://orcid.org/0000-0002-4655-0206)
- Jens Samol (ORCID: https://orcid.org/0000-0001-6109-3528)
- B-Y. Ryoo
- A.B. El-Khoueiry
- Maxime Chénard-Poirier (ORCID: https://orcid.org/0000-0001-5800-0124)
- Giovanni Abbadessa (ORCID: https://orcid.org/0009-0007-2823-1870)
- Asma Kefsi
- Yan Zhang (ORCID: https://orcid.org/0000-0003-4119-7359)
- L. Lepine
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Brown University (US)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Tan Tock Seng Hospital (SG)
- Sanofi (France) (FR)
- University of Ulsan (KR)
- AVEO Oncology (United States) (US)
- National Cancer Centre Japan (JP)
- National University Cancer Institute, Singapore (SG)
- Sanofi (United States) (US)
- USC Norris Comprehensive Cancer Center (US)
- MRC Biostatistics Unit (GB)
- National Cancer Centre Singapore (SG)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104165
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca
- Northwestern University
- Weill Cornell Medical College
- Daiichi Sankyo Europe